SLPI and elafin: One glove, many fingers

Clinical Science

Volumn 110, Issue 1, 2006, Pages 21-35

  Williams, Steven E ^a   Brown, Thomas I ^a,b   Roghanian, Ali ^a   Sallenave, Jean Michel ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Adaptive immunity; Danger model; Defensin; Dendritic cell; Elafin; Innate immunity; Secretory leucocyte protease inhibitor (SLPI)

Indexed keywords

CATHELICIDIN; DEFENSIN; ELAFIN; LIPOPOLYSACCHARIDE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ANTIMICROBIAL ACTIVITY; CELLULAR IMMUNITY; DENDRITIC CELL; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEINASE INHIBITION; REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; HUMANS; IMMUNITY, NATURAL; INFECTION; INFLAMMATION; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; VACCINES; WOUND HEALING;

EID: 30344465763     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20050115     Document Type: Review

References (176)

1. Pancer, Z., Amemiya, C. T., Ehrhardt, G. R. A. et al. (2004) Somatic diversification of variable lymphocyte receptors in the agnathan sea lamrey. Nature (London) 430, 174-180
2. Matzinger, P. (1994) Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045
3. Dallegri, F. and Ottonello, L. (1997) Tissue injury in neutrophilic inflammation. Inflamm. Res. 46, 382-391
4. McElvaney, N. G. and Crystal, R. G. (1997) Proteases and Lung Injury. In The Lung: Scientific Foundations (Crystal, R. G., West, J. B., Weibel, E. R. and Barnes, P. J., eds.), pp. 2205-2217, Lippincott-Raven, Philadelphia
5. Sallenave, J. M. (2000) The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteases in inflammatory lung disease. Respir. Res. 1, 87-92
6. Schalkwijk, J., Wiedow, O. and Hirose, S. (1999) The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem. J. 340, 569-577
7. Hochstrasser, K., Albrecht, G. J., Schonberger, O. L., Rasche, B. and Lempart, K. (1981) An elastase-specific inhibitor from human bronchial mucus. Isolation and characterization. Hoppe Seylers Z. Physiol. Chem. 362, 1369-1375
8. Kramps, J. A. and Klasen, E. C. (1985) Characterization of a low molecular weight anti-elastase isolated from human bronchial secretion. Exp. Lung Res. 9, 151-165
9. Sallenave, J. M. and Ryle, A. P. (1991) Purification and characterization of elastase-specific inhibitor. Sequence homology with mucus proteinase inhibitor. Biol. Chem. Hoppe Seyler 372, 13-21
10. Wiedow, O., Schroder, J. M., Gregory, H., Young, J. A. and Christophers, E. (1990) Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem. 265, 14791-14795
11. Sallenave, J. M. and Silva, A. (1993) Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions. Am. J. Respir. Cell. Mol. Biol. 8, 439-445
12. Molhuizen, H. O., Alkemade, H. A., Zeeuwen, P. L. et al. (1993) SKALP/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. J. Biol. Chem. 268, 12028-12032
13. Schalkwijk, J., de Roo, C. and de Jongh, G. J. (1991) Skin-derived antileukoproteinase (SKALP), an elastase inhibitor from human keratinocytes. Purification and biochemical properties. Biochim. Biophys. Acta 1096, 148-154
14. Sallenave, J. M., Shulmann, J., Crossley, J., Jordana, M. and Gauldie, J. (1994) Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am. J. Respir. Cell. Mol. Biol. 11, 733-741
15. Brown, T. I., Mistry, R., Collie, D. D., Tate, S. and Sallenave, J. M. (2004) Trappin ovine molecule (TOM), the ovine ortholog of elafin, is an acute phase reactant in the lung. Physiol. Genomics 19, 11-21
16. Alkemade, J. A., Molhuizen, H. O., Ponec, M. et al. (1994) SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes. J. Cell. Sci. 107, 2335-2342
17. Betsuyaku, T., Takeyabu, K., Tanino, M. and Nishimura, M. (2002) Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema. Eur. Respir. J. 19, 1051-1057
18. Kuijpers, A. L., Zeeuwen, P. L., de Jongh, G. J. et al. (1996) Skin-derived antileukoproteinase (SKALP) is decreased in pustular forms of psoriasis. A clue to the pathogenesis of pustule formation? Arch. Dermatol. Res. 288, 641-647
19. Kuijpers, A. L., Schalkwijk, J., Rulo, H. F. et al. (1997) Extremely low levels of epidermal skin-derived antileucoproteinase/elafin in a patient with impetigo herpetiformis. Br. J. Dermatol. 137, 123-129
20. Lin, A. L., Johnson, D. A., Stephan, K. T. and Yeh, C. K. (2004) Salivary secretory leukocyte protease inhibitor increases in HIV infection. J. Oral Pathol. Med. 33, 410-416
21. Zelvyte, I., Wallmark, A., Piitulainen, E., Westin, U. and Janciauskiene, S. (2004) Increased plasma levels of serine proteinase inhibitors in lung cancer patients. Anticancer Res. 24, 241-247
22. Ilzecka, J. and Stelmasiak, Z. (2002) Increased serum levels of endogenous protectant secretory leukocyte protease inhibitor in acute ischemic stroke patients. Cerebrovasc. Dis. 13, 38-42
23. Hiemestra, P. S., Fernie-King, B. A., McMichael, J., Lachmann, P. J. and Sallenave, J. M. (2004) Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. Curr. Pharm. Des. 10, 2891-2905
24. Zitnik, R. J., Zhang, J., Kashem, M. A. et al. (1997) The cloning and characterization of a murine secretory leukocyte protease inhibitor cDNA. Biochem. Biophys. Res. Commun. 232, 687-697
25. Song, X. Y., Zeng, L., Wenwen, J. et al. (1999) Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J. Exp. Med. 190, 535-542
26. Farmer, S. J., Fliss, A. E. and Simmen, R. C. (1990) Complementary DNA cloning and regulation of expression of the messenger RNA encoding a pregnancy-associated porcine uterine protein related to human antileukoproteinase. Mol. Endocrinol. 4, 1095-1104
27. Brown, T. I., Mistry, R., Gray, R., Imrie, M., Collie, D. D. and Sallenave, J.-M. (2005) Characterization of the ovine ortholog of secretory leukoprotease inhibitor. Mamm. Genome 16, 621-630
28. Grütter, M. G., Fendrich, G., Huber, R. and Bode, W. (1988) The 2.5 Å X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine α- chymotrypsin. EMBO J. 7, 345-351
29. Saitoh, H., Masuda, T., Shimura, S., Fushimi, T. and Shirato, K. (2001) Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. Am. J. Physiol. Lung Cell. Mol. Physiol. 280, L79-L87
30. Si-Tahar, M., Merline, D., Sitaraman, S. and Madara, J. L. (2000) Constitutive and regulated secretion of secretory leukocyte proteinase inhibitor by human intestinal epithelial cells. Gastroenterology 118, 1061-1071
31. Zhang, Q., Shimoya, K., Moriyama, A. et al. (2001) Production of secretory leukocyte protease inhibitor by human amniotic membranes and regulation of its concentration in amniotic fluid. Mol. Hum. Reprod. 7, 573-579
32. Sallenave, J. M., Silva, A., Marsden, M. E. and Ryle, A. P. (1993) Secretion of mucus proteinase inhibitor and elafin by Clara cell and type II pneumocyte cell lines. Am. J. Respir. Cell. Mol. Biol. 8, 126-133
33. Westin, U., Polling, A., Ljungkrantz, I. and Ohlsson, K. (1999) Identification of SLPI (secretory leukocyte protease inhibitor) in human mast cells using immunohistochemistry and in situ hybridisation. Biol. Chem. 380, 489-493
34. Sallenave, J. M., Si-Tahar, M., Cox, G., Chignard, M. and Gauldie, J. (1997) Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J. Leukocyte Biol. 61, 695-702
35. Mihaila, A. and Tremblay, G. M. (2001) Human alveolar macrophages express elafin and secretory leukocyte protease inhibitor. Z. Naturforsch. 56, 291-297
36. Maruyama, M., Hay, J. G., Yoshimura, K., Chu, C. S. and Crystal, R. G. (1994) Modulation of secretory leukoprotease inhibitor gene expression in human bronchial epithelial cells by phorbol ester. J. Clin. Invest. 94, 368-375
37. Jaumann, F., Elssner, A., Mazur, G., Dobmann, S. and Vogelmeirer, C. (2000) Transforming growth factor-β1 is a potent inhibitor of secretory leukoprotease inhibitor expression in a bronchial epithelial cell line. Munich Lung Transplant Group. Eur. Respir. J. 15, 1052-1057
38. Sorensen, O. E., Cowland, J. B., Theilgaard-Monch, K., Liu, L., Ganz, T. and Borregaard, N. (2003) Wound healing and expression of antimicrobial peptides/ polypeptides in human keratinocytes, a consequence of common growth factors. J. Immunol. 170, 5583-5589
39. van Wetering, S., van der Linden, A. C., van Sterkenburg, M. A., Rabe, K. F., Schalkwijk, J. and Hiemestra, P. S. (2000) Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase in cell-associated SLPI by neutrophil elastase. J. Invest. Med. 48, 359-366
40. van Wetering, S., van der Linden, A. C., van Sterkenburg, M. A. et al. (2000) Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. Am. J. Physiol. Lung Cell. Mol. Physiol. 278, L51-L58
41. Jin, F., Nathan, C. F., Radzioch, D. and Ding, A. (1998) Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect. Immun. 66, 2447-2452
42. Fleming, D. C., King, A. E., Williams, A. R., Critchley, H. O. and Kelly, R. W. (2003) Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium. Fertil. Steril. 79, 856-863
43. King, A. E., Morgan, K., Sallenave, J.-M. and Kelly, R. W. (2003) Differential regulation of secretory leukocyte protease inhibitor and elafin by progesterone. Biochem. Biophys. Res. Commun. 310, 594-599
44. Boudier, C. and Bieth, J. G. (1992) The proteinase: mucus proteinase inhibitor binding stoichiometry. J. Biol. Chem. 267, 4370-4375
45. Kramps, J. A., Te Boekhorst, A. H., Fransen, A. H., Ginsel, L. A. and Dijkman, J. H. (1989) Antileukoprotease is associated with elastin fibres in the extracellular matrix of the human lung. An immunoelectron microscope study. Am. Rev. Respir. Dis. 140, 471-476
46. Wingens, M., van Bergen, B. H., Hiemstra, P. S. et al. (1998) Induction of SLPI (ALP/HUSI-I) in epidermal keratinocytes. J. Invest. Dermatol. 111, 996-1002
47. Cavarra, E., Lucattelli, M., Gambelli, F. et al. (2001) Human SLPI inactivation after cigarette smoke exposure in a new in vivo model of pulmonary oxidative stress. Am. J. Physiol. Lung Cell. Mol. Physiol. 281, L412-L417
48. Ayad, M. S., Knight, K. R., Burdon, J. G. and Brenton, S. (2003) Secretory leukocyte proteinase inhibitor, α-1-antitrypsin deficiency and emphysema: preliminary study, speculation and an hypothesis. Respirology 8, 175-180
49. Taggart, C. C., Lowe, G. J., Greene, C. M. et al. (2001) Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J. Biol. Chem. 276, 33345-33352
50. Sponer, M., Nick, H. P. and Schnebli, H. P. (1991) Different susceptibility of elastase inhibitors to inactivation by proteinases from Staphylococcus aureus and Pseudomonas aeruginosa. Biol. Chem. Hoppe Seyler 372, 963-970
51. Saheki, T., Ito, F., Hagiwara, H. et al. (1992) Primary structure of the human elafin precursor preproelafin deduced from the nucleotide sequence of its gene and the presence of unique repetitive sequences in the prosegment. Biochem. Biophys. Res. Commun. 185, 240-245
52. Francart, C., Dauchez, M., Alix, A. J. and Lippens, G. (1997) Solution structure of R-elafin, a specific inhibitor of elastase. J. Mol. Biol. 268, 666-677
53. Nara, K., Ito, S., Ito, T. et al. (1994) Elastase inhibitor elafin is a new type of proteinase inhibitor which has transglutaminase-mediated anchoring sequence termed 'cementoin'. J. Biochem. (Tokyo) 115, 441-448
54. Tremblay, G. M., Vachon, E., Larouche, C. and Bourbonnais, Y. (2002) Inhibition of human neutrophil elastase-induced acute lung injury in hamsters by recombinant human pre-elafin (trappin-2). Chest 121, 582-588
55. Tremblay, G. M., Wolbink, A. M., Cormier, Y. and Hack, C. E. (2000) Granzyme activity in the inflammed lung is not controlled by endogenous serine proteinase inhibitors. J. Immunol. 165, 3966-3969
56. Pfundt, R., van Ruissen, F., van Vlijment-Willems, I. M. et al. (1996) Constitutive and inducible expression of SKALP/elafin provides anti-elastase defense in human epithelia. J. Clin. Invest. 98, 1389-1399
57. Nonomura, K., Yamanishi, K., Yasuno, H., Nara, K. and Hirose, S. (1994) Up-regulation of elafin/SKALP gene expression in psoriatic epidermis. J. Invest. Dermatol. 103, 88-91
58. Sallenave, J. M., Marsden, M. D. and Ryle, A. P. (1992) Isolation of elafin and elastase-specific inhibitor (ESI) from bronchial secretions. Evidence of sequence homology and immunological cross-reactivity. Biol. Chem. Hoppe Seyler 373, 27-33
59. Suzuki, Y., Furukawa, M., Abe, J., Kasiwagi, M. and Hirose, S. (2000) Localization of porcine trappin-2 (SKALP/elafin) in trachea and large intestine by in situ hybridization and immunohistochemistry. Histochem. Cell. Biol. 114, 15-20
60. King, A. E., Critchley, H. O., Sallenave, J. M. and Kelly, R. W. (2003) Elafin in human endometrium: an antiprotease and antimicrobial molecule expressed during menstruation. J. Clin. Endocrinol. Metab. 88, 4426-4431
61. Tanaka, N., Fujioka, A., Tajima, S., Ishibashi, A. and Hirose, S. (2000) Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1β and tumour necrosis factor-α stimulate its secretion in vitro. Br. J. Dermatol. 143, 728-732
62. Pfundt, R., van Vlijmen-Willems, I., Bergers, M., Wingens, M., Cloin, W. and Schalkwijk, J. (2001) In situ demonstration of phosphorylated c-jun and p38 MAP kinase in epidermal keratinocytes following ultraviolet B irradiation of human skin. J. Pathol. 193, 248-255
63. Pfundt, R., Wingens, M., Bergers, M., Zweers, M., Frenken, M. and Schalkwijk, J. (2000) TNF-α and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway. Arch. Dermatol. Res. 292, 180-187
64. Bingle, T., Tetley, T. D. and Bingle, C. D. (2001) Cytokine-mediated induction of the human elafin gene in pulmonary epithelial cells is regulated by nuclear factor-κB. Am. J. Respir. Cell Mol. Biol. 25, 84-91
65. van Seuningen, I., Audie, J. P., Gosselin, B., Lafitte, J. J. and Davril, M. (1995) Expression of human mucous proteinase inhibitor in respiratory tract: a study by in situ hybridization. J. Histochem. Cytochem. 43, 645-648
66. Reid, P. T., Marsden, M. E., Cunningham, G. A., Haslett, C. and Sallenave, J. M. (1999) Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in type II alveolar epithelial cells. FEBS Lett. 457, 33-37
67. Zeeuwen, P. L., Hendriks, W., de Jong, W. W. and Schalkwijk, J. (1997) Identification and sequence analysis of two new members of the SKALP/elafin and SPAI-2 gene family. Biochemical properties of the transglutaminase substrate motif and suggestions for a new nomenclature. J. Biol. Chem. 272, 20471-20478
68. Furutani, Y., Kato, A., Yasue, H. et al. (1998) Evolution of the trappin multigene family in the Suidae. J. Biochem. (Tokyo) 124, 491-502
69. Furukawa, M., Suzuki, Y., Ghoneim, M. A., Tachibana, S. and Hirose, S. (1996) Cryptic origin of SPAI, a plasma protein with a transglutaminase substrate domain and the WAP motif, revealed by in situ hybridization and immunohistochemistry. J. Biol. Chem. 271, 29517-29520
70. Tamechika, I., Itakura, M., Saruta, Y. et al. (1996) Accelerated evolution in inhibitor domains of porcine elafin family. J. Biol. Chem. 271, 7012-7018
71. Gipson, T. S., Bless, N. M., Shanley, T. P. et al. (1999) Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury. J. Immunol. 162, 3653-3662
72. Tralau, T., Meyer-Hoffert, U., Schroder, J. M. and Wiedow, O. (2004) Human leukocyte elastase and cathepsin G are specific inhibitors of C5a-dependent neutrophil enzyme release and chemotaxis. Exp. Dermatol. 13, 316-325
73. Hiemstra, P. S., Maassen, R. J., Stolk, J. et al. (1996) Antibacterial activity of antileukoprotease. Infect. Immun. 64, 4250-4254
74. Simpson, A. J., Wallace, W. A., Marsden, M. E. et al. (2001) Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection. J. Immunol. 167, 1778-1786
75. Simpson, A. J., Maxwell, A. I., Govan, J. R., Haslett, C. and Sallenave, J. M. (1999) Elafin (elastase-specific inhibitor) has anti-microbial activity against Gram-positive and Gram-negative respiratorv pathogens. FEBS Lett. 452, 309-313
76. Wiedow, O., Harder, J., Bartels, J., Streit, V. and Christophers, E. (1998) Antileukoprotease in human skin: an antibiotic peptide constitutively produced by keratinocytes. Biochem. Biophys. Res. Commun. 248, 904-909
77. Fernie-King, B. A., Seilly, D. J., Davies, A. and Lachmann, P. J. (2002) Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme. Infect. Immun. 70, 4908-4916
78. Tomee, J. F., Hiemstra, P. S., Heinzel-Wieland, R. and Kauffman, H. F. (1997) Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi. J. Infect. Dis. 176, 740-747
79. Meyer-Hoffert, U., Wichmann, N., Schwichtenberg, L., White, P. C. and Wiedow, O. (2003) Supernatants of Pseudomonas aeruginosa induce the Pseudomonas-specific antibiotic elafin in human keratinocytes. Exp. Dermatol. 12, 418-425
80. Shugars, D. C. (1999) Endogenous mucosal antiviral factors of the oral cavity. J. Infect. Dis. 179, S431-S435
81. Wahl, S. M., McNeely, T. B., Janoff, E. N. et al. (1997) Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1. Oral Dis. 3, S64-S69
82. McNeely, T. B., Dealy, M., Dripps, D. J. et al. (1995) Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J. Clin. Invest. 96, 456-464
83. McNeely, T. B., Shugars, D. C., Rosendahl, M. et al. (1997) Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90, 1141-1149
84. Ma, G., Greenwell-Wild, T., Lei, K. et al. (2004) Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J. Exp. Med. 200, 1337-1346
85. King, A. E., Fleming, D. C., Critchley, H. O. and Kelly, R. W. (2002) Regulation of natural antibiotic expression by inflammatory mediators and mimics of infection in human endometrial epithelial cells. Mol. Hum. Reprod. 8, 341-349
86. Levy, O. (2004) Antimicrobial proteins and peptides: anti-infective molecules of mammalian leukocytes. J. Leukocyte Biol. 76, 909-925
87. Chattopadhyay, A., Gray, L. R., Patton, L. L. et al. (2004) Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Infect. Immun. 72, 1956-1963
88. Farquhar, C., VanCott, T. C., Mbori-Ngacha, D. A. et al. (2002) Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J. Infect. Dis. 186, 1173-1176
89. Pillay, K., Coutsoudis, A., Agadzi-Naqvi, A. K. et al. (2001) Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J. Infect. Dis. 183, 653-656
90. Gompertz, S., Bayley, D. L., Hill, S. L. and Stockley, R. A. (2001) Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 56, 36-41
91. Draper, D. L., Landers, D. V., Krohn, M. A. et al. (2000) Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am. J. Obstet. Gynaecol. 183, 1243-1248
92. Duffy, C. L., Phillips, S. L. and Klingelhutz, A. J. (2003) Microarray analysis identifies differentiation-associated genes regulated by human papillomavirus type 16 E6. Virology 314, 196-205
93. Ohta, K., Nakajima, T., Cheah, A. Y. et al. (2004) Elafin-overexpressing mice have improved cardiac function after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 287, H286-H292
94. O'Blenes, S. B., Zaidi, S. H., Cheah, A. Y., McIntyre, B., Kaneda, Y. and Rabinovitch, M. (2000) Gene transfer of the serine elastase inhibitor elafin protects against vein graft degeneration. Circulation 102, III289-III295
95. Zaidi, S. H., Hui, C., Cheah, A. Y. et al. (1999) Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis. J. Clin. Invest. 103, 1211-1219
96. Mulligan, M. S., Desrochers, P. E., Chinnaiyan, A. M. et al. (1993) In vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2. Proc. Natl. Acad. Sci. U.S.A. 90, 11523-11527
97. Rudolphus, A., Stolk, J., Dijkman, J. H. and Kramps, J. A. (1993) Inhibition of lipopolysaccharide induced pulmonary emphysema by intratracheally instilled recombinant secretory leukocyte proteinase inhibitor. Am. Rev. Respir. Dis. 147, 442-447
98. Mitsuhashi, H., Asano, S., Nonaka, T., Hamamura, I., Masuda, K. I. and Kiyoki, M. (1996) Administration of truncated secretory leukoprotease inhibitor ameliorates bleomycin-induced pulmonary fibrosis in hamsters. Am. J. Respir. Crit. Care Med. 153, 369-374
99. Wex, T., Treiber, G., Nilius, M., Vieth, M., Roessner, A. and Malfertheiner, P. (2004) Helicobacter pylori-mediated gastritis induces local downregulation of secretory leukocyte protease inhibitor in the antrum. Infect. Immun. 72, 2383-2385
100. Grobmyer, S. R., Barie, P. S. and Nathan, C. F. (2000) Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit. Care Med. 28, 1276-1282
101. Wang, X., Li, X., Xu, L. et al. (2003) Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury. Mol. Pharmacol. 64, 833-840
102. Vachon, E., Bourbonnais, Y., Bingle, C. D., Rowe, S. J., Janelle, M. F. and Tremblay, G. M. (2002) Anti-inflammatory effect of pre-elafin in lipopolysaccharide-induced acute lung inflammation. Biol. Chem. 383, 1249-1256
103. Zaidi, S. H., You, X. M., Ciura, S., O'Blenes, S., Husain, M. and Rabinovitch, M. (2000) Suppressed smooth muscle proliferation and inflammatory cell invasion after arterial injury in elafin-overexpressing mice. J. Clin. Invest. 105, 1687-1695
104. Cowan, B., Baron, O., Crack, J., Coulber, C., Wilson, G. J. and Rabinovitch, M. (1996) Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits after heterotopic cardiac transplantation. J. Clin. Invest. 97, 2452-2468
105. Murata, E., Sharmin, S., Shiota, H., Shiota, M., Yano, M. and Kido, H. (2003) The effect of topically applied secretory leukocyte protease inhibitor on the eosinophil response in the late phase of allergic conjunctivitis. Curr. Eye Res. 26, 271-276
106. Sehnert, B., Cavcic, A., Bohm, B. et al. (2004) Antileukoproteinase: modulation of neutrophil function and therapeutic effects on anti-type II collagen antibody-induced arthritis. Arthritis Rheum. 50, 2347-2359
107. He, S. H., Xie, H., Zhang, X. J. and Wang, X. J. (2004) Inhibition of histamine release from human mast cells by natural chymase inhibitors. Acta Pharmacol. Sin. 25, 822-826
108. Haslett, C. (1999) Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am. J. Respir. Crit. Care Med. 160, S5-S11
109. Odaka, C., Mizuochi, T., Yang, J. and Ding, A. (2003) Murine macrophages produce secretory leukocyte protease inhibitor during clearance of apoptotic cells: implications for resolution of the inflammatory response. J. Immunol. 171, 1507-1514
110. Henriksen, P. A., Devitt, A., Kotelevtsev, Y. and Sallenave, J. M. (2004) Gene delivery of the elastase inhibitor elafin protects macrophages from neutrophil elastase-mediated impairment of apoptotic cell recognition. FEBS Lett. 574, 80-84
111. Sano, C., Shimizu, T., Sato, K., Kawauchi, H. and Tomioka, H. (2000) Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-β (TGF-β), by lipopolysaccharide-stimulated macrophages. Clin. Exp. Immunol. 121, 77-85
112. Sano, C., Shimizu, T. and Tomioka, H. (2003) Effects of secretory leukocyte protease inhibitor on the tumor necrosis factor-α production and NF-κ B activation of lipopolysaccharide-stimulated macrophages. Cytokine 21, 38-42
113. Ding, A., Thieblemont, N., Zhu, J., Jin, F., Zhang, J. and Wright, S. (1999) Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages. Infect. Immun. 67, 4485-4489
114. Zhu, J., Nathan, C. and Ding, A. (1999) Suppression of macrophage responses to bacterial lipopolysaccharide by a non-secretory form of secretory leukocyte protease inhibitor. Biochim. Biophys. Acta 1451, 219-223
115. Lentsch, A. B. and Ward, P. A. (2000) The NFκ Bb/Iκ B system in acute inflammation. Arch. Immunol. Ther. Exp. 48, 59-63
116. Jin, F. Y., Nathan, C., Radzioch, D. and Ding, A. (1997) Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 88, 417-426
117. Henriksen, P. A., Hitt, M., Xing, Z. et al. (2004) Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-κ B-dependent inflammatory responses of human endothehal cells and macrophages to atherogenic stimuli. J. Immunol. 172, 4535-4544
118. Lentsch, A. B., Jordan, J. A., Czermak, B. J. et al. (1999) Inhibition of NF-κ B activation and augmentation of Iκ Bβ by secretory leukocyte protease inhibitor during lung inflammation. Am. J. Pathol. 154, 239-247
119. Taggart, C. C., Greene, C. M., McElvaney, N. G. and O'Neill, S. (2002) Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced Iκ Bα degradation without affecting phosphorylation or ubiquitination. J. Biol. Chem. 277, 33648-33653
120. Mulligan, M. S., Lentsch, A. B., Huber-Lang, M. et al. (2000) Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am. J. Pathol. 156, 1033-1039
121. Simpson, A. J., Cunningham, G. A., Porteous, D. J., Haslett, C. and Sallenave, J. M. (2001) Regulation of adenovirus-mediated elafin transgene expression by bacterial lipopolysaccharide. Hum. Gene Ther. 12, 1395-1406
122. Sallenave, J. M., Cunningham, G. A., James, R. M., McLachlan, G. and Haslett, C. (2003) Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. Infect. Immun. 71, 3766-3774
123. McMichael, J. W., Roghanian, A., Jiang, L., Rammage, R. and Sallenave, J. M. (2005) The antimicrobial antiprotease elafin binds to lipopolysaccharide and modulates macrophage responses. Am. J. Respir. Cell. Mol. Biol. 32, 1-10
124. Lee, S. K., Lee, S. S., Hirose, S. et al. (2002) Elafin expression in human fetal and adult submandibular glands. Histochem. Cell Biol. 117, 423-430
125. Yoshida, N., Egami, H., Yamashita, J. et al. (2002) Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of human lung. Oncol. Rep. 9, 495-501
126. Westin, U., Nystrom, M., Ljungcrantz, I., Eriksson, B. and Ohlsson, K. (2002) The presence of elafin, SLPI, IL1-RA and STNFα RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation. Mediators Inflamm. 11, 7-12
127. van Bergen, B. H., Andriessen, M. P., Spruijt, K. I., van de Kerkhof, P. C. and Schalkwijk, J. (1996) Expression of SKALP/elafin during wound healing in human skin. Arch. Dermatol. Res. 288, 458-462
128. Ashcroft, G. S., Lei, K., Jin, W. et al. (2000) Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat. Med. 6, 1147-1153
129. Angelov, N., Moutsopoulos, N., Jeong, M. J., Nares, S., Ashcroft, G. and Wahl, S. M. (2004) Aberrant mucosal wound repair in the absence of secretory leukocyte protease inhibitor. Thromb. Haemostasis 92, 288-297
130. Zhu, J., Nathan, C., Jin, W. et al. (2002) Conversion of proepithelm to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 111, 867-878
131. Sumi, Y., Muramatsu, H., Hata, K., Ueda, M. and Muramatsu, T. (2000) Secretory leukocyte protease inhibitor is a novel inhibitor of fibroblast-mediated collagen gel contraction. Exp. Cell Res. 256, 203-212
132. Zhang, D., Simmen, R. C., Michel, F. J., Zhao, G., Vale-Cruz, D. and Simmen, F. A. (2002) Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J. Biol. Chem. 277, 29999-30009
133. Kikuchi, T., Abe, T., Yaekashiwa, M. et al. (2000) Secretory leukoprotease inhibitor augments growth factor production in human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 23, 364-370
134. Vassiliou, E., Sharma, V., Jing, H., Sheibanie, F. and Ganea, D. (2004) Prostaglandin E2 promotes the survival of bone marrow-derived dendritic cells. J. Immunol. 173, 6955-6964
135. Katamura, K., Shintaku, N., Yamauchi, Y. et al. (1995) Prostaglandin E2 at priming of naïve CD4+ T cells inhibits acquisition of ability to produce IFN-γ and IL-2, but not IL-4 and IL-5. J. Immunol. 155, 4604-4612
136. Jing, H., Yen, J. H. and Ganea, D. (2004) A novel signalling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2. J. Biol. Chem. 279, 55176-55186
137. Zhang, Y., DeWitt, D. L., McNeely, T. B., Wahl, S. M. and Wahl, L. M. (1997) Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J. Clin. Invest. 99, 894-900
138. Reference deleted
139. Tremblay, G. M., Sallenave, J. M., Israel-Assayag, E., Cormier, Y. and Gauldie, J. (1996) Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung. Am. J. Respir. Crit. Care Med. 154, 1092-1098
140. Schalkwijk, J., van Vligmen, I. M., Alkemade, J. A. and de Jongh, G. J. (1993) Immunohistochemical localization of SKALP/elafin in psoriatic epidermis. J. Invest. Dermatol. 100, 390-393
141. Schutte, B. C. and McCray, Jr, P. B. (2002) β-Defensins in lung host defense. Annu. Rev. Physiol. 64, 709-748
142. Ganz, T. (2003) Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3, 710-720
143. Aarbiou, J., Rabe, K. F. and Hiemstra, P. S. (2002) Role of defensins in inflammatory lung disease. Ann. Med. 34, 96-101
144. Wilson, C. L., Ouellette, A. J., Satchell, D. P. et al. (1999) Regulation of intestinal α-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 286, 113-117
145. Duits, L. A., Ravensbergen, B., Rademaker, M., Hiemstra, P. S. and Nibbering, P. H. (2002) Expression of β-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells. Immunology 106, 517-525
146. Zanetti, M., Gennaro, R. and Romeo, D. (1995) Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 374, 1-5
147. Sorensen, O., Arnljots, K., Cowland, J. B., Bainton, D. F. and Borregaard, N. (1997) The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 90, 2796-2803
148. Bals, R., Wang, X., Wu, Z. et al. (1998) Human β-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J. Clin. Invest. 102, 874-880
149. Frohm, M., Agerberth, B., Ahangari, G. et al. (1997) The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 272, 15258-15263
150. Agerberth, B., Charo, J., Werr, J. et al. (2000) The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96, 3086-3093
151. Di Nardo, A., Vitiello, A. and Gallo, R. L. (2003) Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J. Immunol. 170, 2274-2278
152. Sorensen, O. E., Follin, P., Johnsen, A. H. et al. (2001) Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97, 3951-3959
153. Yang, D., Chertov, O., Bykovskata, S. N. et al. (1999) β-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286, 525-528
154. Biragyn, A., Ruffini, P. A., Leifer, C. A. et al. (2002) Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 298, 1025-1029
155. Yang, D., Chen, Q., Schmidt, A. P. et al. (2000) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes and T cells. J. Exp. Med. 192, 1069-1074
156. Davidson, D. J., Currie, A. J., Reid, G. S. D. et al. (2004) The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 172, 1146-1156
157. Colaco, C. A. (1998) Towards a unified theory of immunity: dendritic cells, stress proteins and antigen capture. Cell. Mol. Biol. 44, 883-890
158. Jego, G. (2005) Dendritic cells control B cell growth and differentiation. Curr. Dir. Autoimmun. 8, 124-139
159. Knight, S. C., Burke, F. and Bedford, P. A. (2002) Dendritic cells, antigen distribution and the initiation of primary immune responses to self and non-self antigens. Semin. Cancer Biol. 12, 301-308
160. + CTL antiviral activity in the lymph nodes, spleen and skin, but not in the conjunctivae. Microbes Infect. 3, 1063-1072
161. Matzinger, P. (2002) The danger model: a renewed sense of self. Science 296, 301-305
162. Stumbles, P. A., Thomas, J. A., Pimm, C. L. et al. (1998) Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity. J. Exp. Med. 188, 2019-2031
163. Dodge, I. L., Carr, M. W., Cernadas, M. and Brenner, M. B. (2003) IL-6 production by pulmonary dendritic cells impedes Th1 immune responses. J. Immunol. 170, 4457-4464
164. de Jong, E. C., Vieira, P. L., Kalinski, P. et al. (2002) Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J. Immunol. 168, 1704-1709
165. Pulendram, B. (2004) Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 199, 227-250
166. Gan, Y., Shi, Y. E., Bu, L. Y. et al. (2004) Immune responses against Schistosoma japonicum after vaccinating mice with a multivalent DNA vaccine encoding integrated membrane protein Sj23 and cytokine interleukin-12. Chin. Med. J. 117, 1842-1846
167. Hogg, K. G., Kumkate, S. and Mountford, A. P. (2003) IL-10 regulates early IL-12-mediated immune responses induced by the radiation-attenuated schistosome vaccine. Int. Immunol. 15, 1451-1459
168. Zhu, Y., Da'dara, A., Harn, D. et al. (2004) The protective effect of a Schistosoma japonicum Chinese strain 23kDa plasmid DNA vaccine in pigs is enhanced with IL-12. Vaccine 23, 78-83
169. Bennouna, S., Bliss, S. K., Curiel, T. J. and Denkers, E. Y. (2003) Cross-talk in the innate immune system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J. Immunol. 171, 6052-6058
170. Lu, H., Xing, Z. and Brunham, R. C. (2002) GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis. J. Immunol. 169, 6324-6331
171. Biragyn, A., Surenhu, M., Yang, D. et al. (2001) Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with non-immunogenic tumor antigens. J. Immunol. 167, 6644-6653
172. Liu, D. W., Chang, J. L., Tsao, Y. P. et al. (2005) Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody. Int. J. Cancer. 113, 93-100
173. Wang, J., Zganiacz, A. and Xing, Z. (2002) Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation. Vaccine 20, 2887-2898
174. Xing, Z., Tremblay, G. M., Sime, P. J. and Gauldie, J. (1997) Overexpression of granulocyte-macrophage colony-stimulating factor induces pulmonary granulation tissue formation and fibrosis by induction of transforming growth factor-β1 and myofibroblast accumulation. Am. J. Pathol. 150, 59-66
175. Koczulla, A. R. and Bals, R. (2003) Antimicrobial peptides: current status and therapeutic potential. Drugs 63, 389-406
176. McMichael, J. W., Maxwell, A. I., Hayashi, K. et al. (2005) Antimicrobial activity of murine lung cells against Staphylococcus aureus is increased in vitro and in vivo after elafin gene transfer. Infect. Immun. 73, 3609-3617